New Biotic, Inc., received Orphan Designation from the European Medicines Agency (EMA) for RaphaLX™, a biotherapeutic for treatment of Amyotrophic Lateral Sclerosis (ALS).
Read More
Results of an open label, prospective trial of RaphaLX™ probiotic compound in ALS patients. (Avera Institute for Human Genetics).
Read More
New Biotic filed 2 provisional patents on blood diagnostic biomarkers to quantify degrees of excitoxicity in ALS and other neurological and psychiatric disorders with the United States Patent and Trademark Office (USPTO).
Read More
A pilot study on a cohort of 16 ALS patients was initiated. New Biotic, Inc. has a collaboration agreement with the Avera Institute for Human Genetics and the Avera Health system which serve ALS patients throughout SD, portions of MN, IA and NE.
Read More
New Biotic received Orphan Drug Designation (ODD) from the USA FDA for RaphaLX™, a biotherapeutic for treatment of amyotrophic lateral sclerosis (ALS).
Read More